MA55511A - Inhibiteurs de protéine tyrosine phosphatase - Google Patents

Inhibiteurs de protéine tyrosine phosphatase

Info

Publication number
MA55511A
MA55511A MA055511A MA55511A MA55511A MA 55511 A MA55511 A MA 55511A MA 055511 A MA055511 A MA 055511A MA 55511 A MA55511 A MA 55511A MA 55511 A MA55511 A MA 55511A
Authority
MA
Morocco
Prior art keywords
protein tyrosine
tyrosine phosphatase
phosphatase inhibitors
inhibitors
protein
Prior art date
Application number
MA055511A
Other languages
English (en)
Inventor
James F Blake
Mark Laurence Boys
Mark Joseph Chicarelli
Adam W Cook
Mohamed S A Elsayed
Jay Bradford Fell
John P Fischer
Ronald Jay Hinklin
Yutong Jiang
Oren T Mcnulty
Macedonio J Mejia
Martha E Rodriguez
Christina E Wong
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA55511A publication Critical patent/MA55511A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA055511A 2019-04-02 2020-03-30 Inhibiteurs de protéine tyrosine phosphatase MA55511A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962828356P 2019-04-02 2019-04-02
US202062992558P 2020-03-20 2020-03-20

Publications (1)

Publication Number Publication Date
MA55511A true MA55511A (fr) 2022-02-09

Family

ID=70277430

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055511A MA55511A (fr) 2019-04-02 2020-03-30 Inhibiteurs de protéine tyrosine phosphatase

Country Status (24)

Country Link
US (3) US11634417B2 (fr)
EP (1) EP3947367A1 (fr)
JP (2) JP7284830B2 (fr)
KR (1) KR20210146389A (fr)
CN (1) CN113874363A (fr)
AU (1) AU2020251841A1 (fr)
BR (1) BR112021018664A2 (fr)
CA (1) CA3135555C (fr)
CL (1) CL2021002542A1 (fr)
CO (1) CO2021013030A2 (fr)
CR (1) CR20210501A (fr)
CU (1) CU20210080A7 (fr)
DO (1) DOP2021000206A (fr)
EC (1) ECSP21072994A (fr)
GE (1) GEP20237561B (fr)
IL (1) IL286462A (fr)
MA (1) MA55511A (fr)
MX (1) MX2021012122A (fr)
PE (1) PE20220141A1 (fr)
SG (1) SG11202110502PA (fr)
TW (1) TWI766261B (fr)
UY (1) UY38628A (fr)
WO (1) WO2020201991A1 (fr)
ZA (1) ZA202108443B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (fr) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CN117083285A (zh) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
KR20230165309A (ko) 2021-04-01 2023-12-05 어레이 바이오파마 인크. Shp2 억제제의 결정질 형태
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ras阻害剤及びその使用
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技(上海)有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115960109A (zh) * 2021-05-31 2023-04-14 药雅科技(上海)有限公司 稠环类shp2磷酸酶抑制剂的制备及其应用
AU2022309195A1 (en) 2021-07-09 2024-01-25 Kanaph Therapeutics Inc. Shp2 inhibitor and use thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023061263A1 (fr) * 2021-10-14 2023-04-20 北京泰德制药股份有限公司 Inhibiteur de shp2, composition pharmaceutique le comprenant et son utilisation
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023180898A1 (fr) 2022-03-23 2023-09-28 Array Biopharma Inc. Forme de sel cristallin d'un inhibiteur de shp2
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US10280171B2 (en) 2016-05-31 2019-05-07 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
SG11201401460PA (en) 2011-10-14 2014-09-26 Array Biopharma Inc POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112015004548A2 (pt) 2012-08-27 2017-08-08 Array Biopharma Inc inibidores de serina/treonina para tratamento de doenças hiperproliferativas
US9403831B2 (en) 2013-09-30 2016-08-02 Korea Research Institute Of Chemical Technology Triazolopyrazine derivative and use thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6473457B2 (ja) * 2014-01-17 2019-02-20 ノバルティス アーゲー Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
WO2016203405A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP3310779B1 (fr) 2015-06-19 2019-05-08 Novartis AG Composés et compositions pour l'inhibition de l'activité de shp2
EP4108659A1 (fr) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs shp2
EA036446B1 (ru) 2016-06-14 2020-11-11 Новартис Аг Соединения и композиции для подавления активности shp2
CN116478132A (zh) 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
EP3515916B1 (fr) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
AU2018239542C1 (en) * 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
CA3074690A1 (fr) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Compositions d'inhibiteur de la shp2 et methodes de traitement du cancer
EP3681879A1 (fr) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
EP3694848A1 (fr) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine et composés de triazine utilisés en tant qu'inhibiteurs allostériques de shp2
EP3724189B1 (fr) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Composés polycycliques comme inhibiteurs allosteriques de la shp2
WO2019152454A1 (fr) 2018-01-30 2019-08-08 Research Development Foundation Inhibiteurs de shp2 et méthodes d'utilisation associées
WO2019183364A1 (fr) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase pyrazolo[3,4-b]pyrazine shp2 et leurs procédés d'utilisation
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
EP3768668A1 (fr) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase shp2 et leurs procédés d'utilisation
SG11202100199UA (en) 2018-08-10 2021-02-25 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
CN112839935A (zh) * 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
PE20211465A1 (es) 2018-10-17 2021-08-05 Array Biopharma Inc Inhibidores de la proteina tirosina fosfatasa

Also Published As

Publication number Publication date
TW202102490A (zh) 2021-01-16
DOP2021000206A (es) 2021-11-21
CA3135555C (fr) 2023-09-19
US20200317665A1 (en) 2020-10-08
PE20220141A1 (es) 2022-01-27
CR20210501A (es) 2021-11-02
CN113874363A (zh) 2021-12-31
SG11202110502PA (en) 2021-10-28
IL286462A (en) 2021-10-31
ZA202108443B (en) 2023-04-26
CL2021002542A1 (es) 2022-06-24
TWI766261B (zh) 2022-06-01
KR20210146389A (ko) 2021-12-03
MX2021012122A (es) 2021-11-03
CU20210080A7 (es) 2022-05-11
CA3135555A1 (fr) 2020-10-08
US11884664B2 (en) 2024-01-30
AU2020251841A1 (en) 2021-10-07
CO2021013030A2 (es) 2021-10-20
JP2022527796A (ja) 2022-06-06
US20220251083A1 (en) 2022-08-11
JP7284830B2 (ja) 2023-05-31
ECSP21072994A (es) 2021-11-18
US20240124453A1 (en) 2024-04-18
US11634417B2 (en) 2023-04-25
GEP20237561B (en) 2023-10-25
JP2023078421A (ja) 2023-06-06
EP3947367A1 (fr) 2022-02-09
WO2020201991A1 (fr) 2020-10-08
BR112021018664A2 (pt) 2021-11-23
UY38628A (es) 2020-10-30

Similar Documents

Publication Publication Date Title
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
MA55511A (fr) Inhibiteurs de protéine tyrosine phosphatase
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3844147T3 (da) Forbindelser
IL286373A (en) Protein tyrosine phosphatase inhibitor compounds and uses thereof
MA52413A (fr) Inhibiteurs de cd73
MA51616A (fr) Inhibiteurs d&#39;adn-pk
MA52812A (fr) Inhibiteurs de sarm1
MA49908A (fr) Composés inhibant la protéine mcl-1
MA53287A (fr) Inhibiteurs de prmt5
MA52635A (fr) Inhibiteurs de magl
CL2021000426A1 (es) Inhibidores de la interacción proteína-proteína keap1-nrf2.
MA55909A (fr) Inhibiteurs de cdk
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
MA50675A (fr) Inhibiteurs de la creb binding protein (cbp)
MA55477A (fr) Inhibiteurs de hpk1
MA51611A (fr) Inhibiteurs de pi4kiiibêta
DK3591122T3 (da) Hurtigskifter
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
DK3797662T3 (da) Vippedyvel
TH191170S (th) เสื้อสูบสำหรับเครื่องยนต์
AR128365A1 (es) Inhibidores de parp7
UA41551S (uk) Пательня